Changes in the gut microbiome associated with infliximab in patients with bipolar disorder

Study information

Needs review

study design

randomized controlled trial

Citation

PMID PubMed identifier for scientific articles.

34152099

DOI Digital object identifier for electronic documents.

10.1002/brb3.2259

URI

Authors

Bharwani A, Szamosi JC, Taylor VH, Lee Y, Bala A, Mansur R, Subramaniapillai M, Surette M, McIntyre RS

Journal

Brain and behavior

Year

2021

Keywords:

16S rRNA sequencing, bipolar disorder, gut microbiota, inflammation, infliximab

OBJECTIVES: Available information exists supporting the gut-brain axis, but additional information is needed to explore how the gut microbiome changes when exposed to mood disorder treatments. We sought to explore the effects of a novel treatment for bipolar disorder (BD), infliximab, on the gut microbiome. METHODS: Participants with a primary diagnosis of BD (n = 15) who participated in a 12-week, randomized placebo-controlled trial evaluating the efficacy of adjunctive infliximab in the treatment of BD were recruited and followed. Stool samples were collected prior to randomization and at 12 weeks. 16S rRNA sequencing was employed in order to analyze the gut microbial community profile. RESULTS: A total of 17 participants were randomized to infliximab (n = 9; mean [SD] age, 47.6 [10.3] years; 8 female) or to placebo (n = 8; mean [SD] age, 45.9 [10.7] years; 7 female) but two participants from the infliximab group were lost to follow-up post randomization. Across all time points, there were no differences in the diversity on either Shannon or Simpson's Diversity indices. Comparison of Aitchison distances revealed a lack of clustering of the microbiota by time point, but did reveal a small overall effect of treatment that was not significantly different at individual time points. There were also no effects of either time or treatment on differential abundance at either the amplicon sequence variant or genus level. CONCLUSIONS: These observations indicate that no community-wide changes in the microbiota diversity and profile were detected after the use of infliximab treatment.

Experiment 1

Edit History Delete

Mark reviewed

Your review change was submittedDuplicate this Experiment Add a new Signature

Needs review

Curated date: 2024/07/27

Curator: JoyceQ

Revision editor(s): JoyceQ

Subjects

Location of subjects: Canada

Host species Species from which microbiome was sampled. Contact us to have more species added.: Homo sapiens

Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology: Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces

Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology: Bipolar disorder [X]Bipolar affective disorder, unspecified,[X]Bipolar affective disorder, unspecified (disorder),Affective Bipolar Psychosis,Affective Psychosis, Bipolar,Bipolar affective disorder,bipolar affective disorder,Bipolar affective disorder , current episode mixed (disorder),Bipolar affective disorder, current episode depression (disorder),Bipolar affective disorder, manic, unspecified degree,Bipolar affective disorder, mixed, unspecified degree,Bipolar Affective Psychosis,Bipolar Depression,bipolar depression,BIPOLAR DIS,bipolar disease,bipolar disorder,Bipolar disorder (disorder),bipolar disorder manic phase,BIPOLAR DISORDER NOS,Bipolar disorder, NOS,Bipolar disorder, unspecified,Bipolar Disorders,Depression, Bipolar,Depressive-manic psych.,depressive-manic psych.,Disorder, Bipolar,Disorder, Manic,MAFD,major affective disorder,major bipolar affective disorder,Mania,Manias,Manic Bipolar Affective disorder,manic bipolar affective disorder,Manic bipolar I disorder,manic bipolar I disorder,Manic bipolar I disorder (disorder),manic depression,Manic Depressive disorder,manic depressive disorder,MANIC DEPRESSIVE ILLNESS,Manic Depressive Psychosis,MANIC DIS,Manic Disorder,manic disorder,Manic Disorders,Manic State,Manic States,Manic-Depression,manic-depression,Manic-depressive illness,manic-depressive illness,Manic-Depressive Psychoses,Manic-depressive psychosis,manic-depressive psychosis,Manic-depressive syndrome NOS,MDI - Manic-depressive illness,mixed bipolar affective disorder (disorder),mixed bipolar affective disorder, NOS (disorder),mixed bipolar disorder,mixed bipolar I disorder (disorder),Psychoses, Bipolar Affective,Psychoses, Manic Depressive,Psychoses, Manic-Depressive,Psychosis, Bipolar Affective,Psychosis, Manic Depressive,Psychosis, Manic-Depressive,State, Manic,States, Manic,Unspecified bipolar affective disorder,Unspecified bipolar affective disorder (disorder),Unspecified bipolar affective disorder, NOS,Unspecified bipolar affective disorder, NOS (disorder),Unspecified bipolar affective disorder, unspecified,Unspecified bipolar affective disorder, unspecified (disorder),Bipolar disorder

Group 0 name Corresponds to the control (unexposed) group for case-control studies: Placebo

Group 1 name Corresponds to the case (exposed) group for case-control studies: Infliximab

Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group: Participants who received infliximab, an antibody administered intravenously that is used for treating several chronic inflammatory diseases and works by blocking the effects of TNF-α

Group 0 sample size Number of subjects in the control (unexposed) group: 8

Group 1 sample size Number of subjects in the case (exposed) group: 9

Lab analysis

Sequencing type: 16S

16S variable region One or more hypervariable region(s) of the bacterial 16S gene: Not specified

Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance: Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).: raw counts

Statistical test: PERMANOVA; ANCOM

Significance threshold p-value or FDR threshold used for differential abundance testing (if any): 0.05

MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?: No

Matched on Factors on which subjects have been matched on in a case-control study: bipolar disorder

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness: unchanged

Simpson Estimator of species richness and species evenness: more weight on species evenness: unchanged